Wells Fargo & Company MN boosted its position in shares of Perrigo (NYSE:PRGO) by 7.9% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 169,900 shares of the company’s stock after acquiring an additional 12,491 shares during the period. Wells Fargo & Company MN owned about 0.12% of Perrigo worth $14,808,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Victory Capital Management Inc. raised its position in Perrigo by 90.5% in the 4th quarter. Victory Capital Management Inc. now owns 2,046,980 shares of the company’s stock valued at $178,414,000 after purchasing an additional 972,210 shares during the last quarter. Greenlight Capital Inc. raised its position in Perrigo by 14.8% during the 3rd quarter. Greenlight Capital Inc. now owns 2,901,032 shares of the company’s stock worth $245,572,000 after buying an additional 374,032 shares during the last quarter. Asset Management One Co. Ltd. raised its position in Perrigo by 5,856.9% during the 3rd quarter. Asset Management One Co. Ltd. now owns 190,501 shares of the company’s stock worth $16,126,000 after buying an additional 187,303 shares during the last quarter. Dimensional Fund Advisors LP raised its position in Perrigo by 40.8% during the 3rd quarter. Dimensional Fund Advisors LP now owns 622,690 shares of the company’s stock worth $52,699,000 after buying an additional 180,348 shares during the last quarter. Finally, Point72 Asset Management L.P. acquired a new position in shares of Perrigo during the 3rd quarter worth $12,706,000. Institutional investors own 79.11% of the company’s stock.
In related news, CEO Uwe Roehrhoff purchased 7,500 shares of the firm’s stock in a transaction dated Monday, March 5th. The stock was acquired at an average price of $81.85 per share, with a total value of $613,875.00. Following the completion of the transaction, the chief executive officer now owns 4,900 shares of the company’s stock, valued at $401,065. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 6.90% of the stock is currently owned by company insiders.
Shares of NYSE:PRGO opened at $81.99 on Friday. The company has a debt-to-equity ratio of 0.53, a current ratio of 1.96 and a quick ratio of 1.40. Perrigo has a 52-week low of $63.68 and a 52-week high of $95.93. The company has a market capitalization of $11,744.11, a price-to-earnings ratio of 16.63, a PEG ratio of 2.07 and a beta of 0.76.
Perrigo (NYSE:PRGO) last released its quarterly earnings results on Thursday, March 1st. The company reported $1.28 earnings per share for the quarter, topping analysts’ consensus estimates of $1.25 by $0.03. Perrigo had a net margin of 2.42% and a return on equity of 11.54%. The business had revenue of $1.28 billion during the quarter, compared to the consensus estimate of $1.26 billion. During the same quarter last year, the company earned $1.24 earnings per share. The business’s quarterly revenue was down 3.6% compared to the same quarter last year. analysts anticipate that Perrigo will post 5.23 EPS for the current fiscal year.
The business also recently declared a quarterly dividend, which was paid on Tuesday, March 20th. Stockholders of record on Friday, March 2nd were given a dividend of $0.19 per share. The ex-dividend date was Thursday, March 1st. This represents a $0.76 dividend on an annualized basis and a dividend yield of 0.93%. This is an increase from Perrigo’s previous quarterly dividend of $0.16. Perrigo’s dividend payout ratio (DPR) is presently 15.42%.
A number of research firms have recently weighed in on PRGO. Canaccord Genuity set a $105.00 price target on shares of Perrigo and gave the stock a “buy” rating in a research note on Monday, March 26th. Leerink Swann began coverage on shares of Perrigo in a research note on Tuesday, January 2nd. They set a “market perform” rating and a $90.00 price target on the stock. Oppenheimer set a $98.00 price objective on shares of Perrigo and gave the company a “buy” rating in a research note on Monday, March 5th. Finally, Cantor Fitzgerald set a $107.00 price objective on shares of Perrigo and gave the company a “buy” rating in a research note on Friday, January 19th. One research analyst has rated the stock with a sell rating, ten have issued a hold rating and nine have assigned a buy rating to the company. The stock has an average rating of “Hold” and a consensus price target of $91.88.
COPYRIGHT VIOLATION NOTICE: This piece of content was originally published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece of content on another publication, it was illegally copied and republished in violation of US and international copyright laws. The original version of this piece of content can be read at https://www.dispatchtribunal.com/2018/04/07/wells-fargo-company-mn-has-14-81-million-holdings-in-perrigo-company-plc-prgo.html.
Perrigo Company plc, a healthcare company, manufactures and supplies over-the-counter (OTC) healthcare products, infant formulas, branded OTC products, and generic pharmaceutical products worldwide. The company operates through Consumer Healthcare Americas, Consumer Healthcare International, and Prescription Pharmaceuticals segments.
Receive News & Ratings for Perrigo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Perrigo and related companies with MarketBeat.com's FREE daily email newsletter.